氢可酮,临床注释,变异和临床注释数据

id	等位基因	注释文本
220	*41	The CYP2D641 allele is assigned as a decreased function allele by CPIC. Patients carrying the 41 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.
219	*17	The CYP2D617 allele is assigned as a decreased function allele by CPIC. Patients carrying the 17 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.
218	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.
217	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.
216	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients carrying the 2 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.
215	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.

等位基因

注释文本

The CYP2D6*41 allele is assigned as a decreased function allele by CPIC. Patients carrying the *41 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.

219

*17

The CYP2D6*17 allele is assigned as a decreased function allele by CPIC. Patients carrying the *17 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.

218

The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.

217

The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.

216

The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.

215

The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.

id	证据的ID	总结
14580	1451155490	CYP2D6 4/4 is associated with decreased concentrations of hydromorphone in human liver microsome as compared to CYP2D6 1/1 + 1/4.
14496	1445117515	CYP2D6 poor metabolizer is associated with decreased metabolism of hydrocodone as compared to CYP2D6 ultrarapid metabolizer phenotype.
14495	1183683979	CYP2D6 normal metabolizer phenotype is associated with increased metabolism of hydrocodone as compared to CYP2D6 poor metabolizer phenotype.
14494	PA166228121	Annotation of CPIC Guideline for hydrocodone and CYP2D6
14413	1451141840	CYP2D6 5/17 is associated with decreased concentrations of hydromorphone in women.
14412	1449189944	CYP2D6 2/41 is associated with increased concentrations of hydrocodone.
14411	1447948869	CYP2D6 poor metabolizers are associated with decreased metabolism of hydrocodone in healthy individuals as compared to CYP2D6 normal metabolizer and ultra-metabolizer.

证据的ID

总结

14580

1451155490

CYP2D6 *4/*4 is associated with decreased concentrations of hydromorphone in human liver microsome as compared to CYP2D6 *1/*1 + *1/*4.

14496

1445117515

CYP2D6 poor metabolizer is associated with decreased metabolism of hydrocodone as compared to CYP2D6 ultrarapid metabolizer phenotype.

14495

1183683979

CYP2D6 normal metabolizer phenotype is associated with increased metabolism of hydrocodone as compared to CYP2D6 poor metabolizer phenotype.

14494

PA166228121

Annotation of CPIC Guideline for hydrocodone and CYP2D6

14413

1451141840

CYP2D6 *5/*17 is associated with decreased concentrations of hydromorphone in women.

14412

1449189944

CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.

14411

1447948869

CYP2D6 poor metabolizers are associated with decreased metabolism of hydrocodone in healthy individuals as compared to CYP2D6 normal metabolizer and ultra-metabolizer.

id	类型	评论
499	Update	CA score added as part of scoring system release. LOE assigned following curator review.
498	Update	Minor edits to phenotype descriptions
497	Update	Added PMIDs 7693389, 24269714, 25621429, 20837591 and 14998425 to evidence, added more star alleles and phenotype descriptions and updated biogeographical information. LOE changed to 3 to reflect addition of new evidence.
496	Create	Created

类型

499

Update

CA score added as part of scoring system release. LOE assigned following curator review.

498

Update

Minor edits to phenotype descriptions

497

Update

Added PMIDs 7693389, 24269714, 25621429, 20837591 and 14998425 to evidence, added more star alleles and phenotype descriptions and updated biogeographical information. LOE changed to 3 to reflect addition of new evidence.

496

Create